RxSight announces Alcon lens deal as analysts target RxSight stock at USD 8.17. Published on 10/16/2026 at 03:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS The October 15, 2026 deal pairs RxSight's adjustable lens technology with Alcon's designs. Twelve firms assign RxSight stock a USD 8.17 consensus target. Collaboration and financial pressure. * RxSight and Alcon agreed on a collaboration worth up to USD 200 million on October 15, 2026. * Second-quarter revenue reached USD 33.7 million, while product sales totaled USD 27.2 million. * Twelve firms assign RxSight a USD 8.17 consensus target. * MarketBeat estimates the next results date as November 4, 2026. * RxSight had a USD 194.2 million market capitalization as of October 15, 2026. RxSight (ISIN US78349D1072) and Alcon announced a non-exclusive collaboration on October 15, 2026, to develop adjustable presbyopia-correcting intraocular lenses with up to USD 200 million in upfront and milestone payments, according to Latham and Watkins. The agreement combines RxSight's post-operative light-adjustable technology with Alcon's optical designs. Discover more Invest in Stocks What does the Alcon deal add? The collaboration gives RxSight a route into presbyopia-correcting lenses while its existing platform remains centered on cataract surgery. The company recognized USD 6.5 million of collaboration revenue in the second quarter of 2026, and its June 30, 2026 balance sheet included USD 208.8 million in cash, cash equivalents and short-term investments, according to RxSight. Why margins still matter. RxSight reported USD 33.7 million of revenue in the second quarter of 2026, including the Alcon contribution, compared with USD 33.6 million in the year-ago quarter. Product sales fell 19 percent year over year to USD 27.2 million, while gross margin excluding collaboration revenue declined to 71.2 percent from 74.9 percent, according to RxSight. The company posted a GAAP net loss of USD 12.1 million, or USD 0.29 per diluted share, for that period. Analyst sentiment remains cautious. MarketBeat reported on October 3, 2026, that twelve firms assigned an average Reduce rating and a USD 8.17 12-month target. The group included three sell ratings, seven hold ratings and two buy ratings. When does RxSight report again? MarketBeat estimates that RxSight will report third-quarter 2026 results on November 4, 2026, after the market closes. The estimate puts the next report at the center of the debate over product demand, collaboration revenue and operating costs. Discover more Stock market analysis NASDAQ stock quotes Eye health blog Stock valuation and next catalyst. RxSight's latest Nasdaq quote was USD 4.67 on October 15, 2026 at 4:00 p.m. ET. The stock had a USD 194.2 million market capitalization and a 52-week range of USD 4.40 to USD 16.74 as of that date. The next reported figures will show whether the Alcon collaboration can offset weaker product sales. RxSight key facts. * Company: RxSight, Inc. * ISIN: US78349D1072 * Ticker: RXST * Primary exchange: Nasdaq * Primary quote: USD 4.67 on October 15, 2026 at 4:00 p.m. ET * Market capitalization: USD 194.2 million (as of October 15, 2026) * 52-week range: USD 4.40-16.74 (as of October 15, 2026) * Sector / Industry: Healthcare / Medical Devices Sponsored Ad Discover more Order Contacts Source Med Gear Find Vision Aids Rxsight stock: new analysis - 21 October. Fresh Rxsight information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US78349D1072 | RXST | boerse | 70334533 | bgmi

RxSight realigns top management. Tarsus Pharmaceuticals CCO is now leading the company. September 24, 2026 Managing Editor, Rodman Media There's a new tenant in RxSight Inc.'s corner office. The company has appointed Aziz Mottiwala as president and CEO, succeeding Ron Kurtz, M.D., who will continue to serve as chief medical officer. "We are excited to welcome Aziz to RxSight and believe his deep commercial and operational experience in eye care makes him exceptionally well suited to lead the company into its next chapter of value creation," RxSight Board Chairman Andy Corley stated. "On behalf of the board, I want to express our sincere appreciation to Ron for his vision and leadership in establishing adjustability in the ophthalmic marketplace, and for his continued commitment to advancing our technology and clinical value as chief medical officer. Ron's track record of product development is well known throughout the ophthalmic community, and we look forward to his continued leadership as we expand adjustability into broader market segments." Mottiwala has extensive commercial leadership experience across eye care, with a proven track record of building and scaling high-performing commercial organizations. He most recently served as chief commercial officer at Tarsus Pharmaceuticals and previously held the same role at Opiant Pharmaceuticals. Before that, he spent more than a decade at Allergan, where he held senior leadership positions across the company's eye care franchise and broader commercial organization. Mottiwala earned a bachelor of science degree in biochemistry from the University of California, San Diego, and an MBA from the University of Southern California. "I am excited and honored to join RxSight at such a critical time for the company," Mottiwala said. "RxSight has created a unique and differentiated platform with significant opportunity ahead. Adjustability has brought a new level of accuracy and customization to modern cataract surgery that is still in the early stages of market adoption." In connection with this transition, Dr. Kurtz resigned from the Board of Directors; Mottiwala assumed his spot on the governing body. "RxSight is well positioned to further its mission of transforming cataract surgery through adjustability, making this the right time for me to focus on areas where I can have the greatest impact," Dr. Kurtz commented. "I look forward to working closely with Aziz, the RxSight team, and our clinical partners to continue bringing life-changing innovations and personalized vision to patients." RxSight Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight Light Adjustable Lens system, comprising the RxSight Light Adjustable Lens (LAL/LAL+, collectively the LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery, according to the company. Add us as a preferred source on Google. Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

RxSight (NASDAQ:RXST) COO Ilya Goldshleger sells 2,041 shares of stock. September 2, 2026 Key points. * RxSight COO Ilya Goldshleger sold 2,041 shares at an average price of $6.96, generating $14,205.36. The sale covered tax withholding obligations tied to vested equity awards, reducing his holdings by 2.44% to 81,509 shares. * RxSight shares rose 0.6% to $7.03, with the company valued at approximately $292.4 million. Its stock has traded between $4.48 and $13.22 over the past year. * The company recently exceeded quarterly expectations, reporting a loss of $0.29 per share versus the projected $0.33 loss and revenue of $33.74 million. Analyst sentiment remains cautious, with an average "Reduce" rating and an average price target of $8.37. * MarketBeat previews the top five stocks to own by October 1st. RxSight, Inc. (NASDAQ:RXST - Get Free Report) COO Ilya Goldshleger sold 2,041 shares of the business's stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $6.96, for a total transaction of $14,205.36. Following the completion of the sale, the chief operating officer owned 81,509 shares in the company, valued at $567,302.64. This represents a 2.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. RxSight trading up 0.6%. NASDAQ:RXST traded up $0.04 during midday trading on Wednesday, hitting $7.03. 778,865 shares of the company traded hands, compared to its average volume of 898,096. The firm has a market capitalization of $292.40 million, a P/E ratio of -6.22 and a beta of 1.16. RxSight, Inc. has a 12-month low of $4.48 and a 12-month high of $13.22. The firm's fifty day moving average is $5.95 and its 200-day moving average is $6.35. RxSight (NASDAQ:RXST - Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.33) by $0.04. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.35%. The company had revenue of $33.74 million for the quarter, compared to the consensus estimate of $32.55 million. On average, research analysts expect that RxSight, Inc. will post -1.01 EPS for the current fiscal year. Wall Street analyst weigh in. A number of equities analysts have commented on RXST shares. Needham & Company LLC reissued a "buy" rating and set a $11.00 target price on shares of RxSight in a report on Tuesday, July 7th. Bank of America dropped their price objective on shares of RxSight from $8.00 to $6.50 and set an "underperform" rating for the company in a report on Tuesday, July 7th. Stifel Nicolaus decreased their price objective on shares of RxSight from $8.00 to $7.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Jefferies Financial Group set a $6.50 target price on shares of RxSight in a research report on Tuesday, July 7th. Finally, UBS Group boosted their price objective on RxSight from $5.50 to $6.30 and gave the company a "neutral" rating in a research note on Thursday, August 6th. Two investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Reduce" and an average target price of $8.37. Institutional trading of RxSight. Hedge funds and other institutional investors have recently bought and sold shares of the company. Raymond James Financial Inc. purchased a new position in shares of RxSight in the 2nd quarter worth $28,000. Summit Securities Group LLC purchased a new position in shares of RxSight in the first quarter valued at $30,000. Larson Financial Group LLC grew its stake in shares of RxSight by 110.5% during the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company's stock valued at $36,000 after acquiring an additional 2,089 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its holdings in RxSight by 440.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 3,758 shares of the company's stock worth $39,000 after purchasing an additional 3,063 shares during the last quarter. Finally, CWM LLC raised its holdings in RxSight by 211.1% in the fourth quarter. CWM LLC now owns 3,826 shares of the company's stock valued at $40,000 after acquiring an additional 2,596 shares in the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors. About RxSight. RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company's flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non-invasive post-operative adjustments. Using ultraviolet light, surgeons can fine-tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction. Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider RxSight, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and RxSight wasn't on the list. While RxSight currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys. Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain - combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.